Fractyl Health, Inc. (GUTS) remains a clinical-stage company developing novel therapies for obesity and type 2 diabetes with its Revita device and Rejuva gene therapy candidates. While pivotal trial data for Revita are expected throughout 2026, the company faces significant net losses and operating cash flow deficits that raise substantial doubt about its ability to continue beyond early 2027 without additional capital. Cash reserves of $81.5 million at year-end 2025 provide some runway, but ongoing financing or partnerships will be critical to sustain operations amid regulatory complexities and competitive pressures.